Self-propagating, infectious, virus-like particles are generated in animal cell lines transfected with a Semliki Forest virus RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus (VSV) glycoprotein. We show here that these infectious particles, which we call propagating replicons, are potent inducers of neutralizing antibody in animals yet are nonpathogenic. Mice vaccinated with a single dose of the particles generated high titers of VSV-neutralizing antibody and were protected from a subsequent lethal challenge with VSV. Induction of antibody required RNA replication. We also report that additional genes (including an HIV-1 envelope protein gene) expressed from the propagating replicons induced strong cellular immune responses to the corresponding proteins after a single inoculation. Our studies reveal the potential of these particles as simple and safe vaccine vectors inducing strong humoral and cellular immune responses.
Self-propagating, infectious, virus-like particles are generated in animal cell lines transfected with a Semliki Forest virus RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus (VSV) glycoprotein. We show here that these infectious particles, which we call propagating replicons, are potent inducers of neutralizing antibody in animals yet are nonpathogenic. Mice vaccinated with a single dose of the particles generated high titers of VSV-neutralizing antibody and were protected from a subsequent lethal challenge with VSV. Induction of antibody required RNA replication. We also report that additional genes (including an HIV-1 envelope protein gene) expressed from the propagating replicons induced strong cellular immune responses to the corresponding proteins after a single inoculation. Our studies reveal the potential of these particles as simple and safe vaccine vectors inducing strong humoral and cellular immune responses.
Semliki Forest virus ͉ vesicular stomatitis virus ͉ HIV-1 R NA replicons from alphaviruses including Semliki Forest virus (SFV) have been developed and used for transient expression of foreign proteins in mammalian cells and also as experimental vaccine vectors (1) (2) (3) (4) . The alphavirus genome is a capped and polyadenylated positive-strand RNA molecule Ϸ12 kb in length. The genomic RNA itself is an mRNA that encodes the viral replicase. A subgenomic mRNA copied from the antigenomic RNA after replication encodes the alphavirus structural proteins. RNA transcribed from SFV cDNA can initiate viral RNA replication following transfection into cells (5) .
Our laboratory previously tested an SFV replicon developed by Liljeström and Garoff (5) for expression of the vesicular stomatitis virus (VSV) glycoprotein (G) (6) . The starting SFV RNA replicon was derived from a DNA copy of SFV from which the genes for the SFV structural proteins were removed. The VSV G gene was inserted in place of genes encoding the SFV structural proteins. VSV G protein is the single transmembrane glycoprotein of the prototype rhabdovirus VSV. VSV G mediates both virus binding and membrane fusion to allow viral entry (7, 8) . When this SFVG replicon RNA expressing only the SFV replication proteins and VSV G protein was transfected into BHK-21 cells, it initially replicated in the small fraction of transfected cells. Surprisingly, it also produced infectious, low density, membrane-enveloped particles lacking a nucleocapsid protein that budded from the cells and infected and killed all cells in the culture within 2-3 days. These infectious particles could be propagated (passaged) indefinitely in tissue culture, and their infectivity was inactivated by a VSV-neutralizing antibody that binds the VSV G protein (6, 9) . Although the precise mechanism of generation of the SFVG infectious particles remains unknown, it clearly involves release of vesicles containing VSV G protein and SFV RNA. The replication of all positive-strand RNA viruses including SFV occurs in association with cellular membranes (10) . SFV replication occurs in association with cytopathic vacuoles containing invaginations called spherules, which are probably the sites of SFV RNA synthesis (11) (12) (13) . These spherules are also seen on the surface of SFVinfected cells (12) and could be precursors involved in formation of the infectious particles containing VSV G (6).
Experimental SFV particle-based vaccines are normally derived from a complementation/packaging system in which SFV replicons encoding foreign antigenic proteins are packaged into SFV-like particles by SFV structural proteins expressed in trans (5) . Such a complementation system is required for alphavirus vector systems because of the strict size limit for encapsidation of viral genomic RNA. Unless the structural genes are deleted, there is no space for inclusion of genes expressing foreign antigens. Because these complemented particles do not encode SFV structural proteins, they replicate for only a single cycle when inoculated into animals.
The hybrid SFV/VSV propagating replicon particles that we described infect and propagate in certain cell lines (6) with VSV G as the only viral structural protein. However, the immunogenicity of these particles (designated SFVG particles) had not been tested in an animal model. Here we have examined the potential of these particles as a vaccine vector in a mouse model. We found that the particles induced a potent neutralizing antibody response to VSV in mice. Mice vaccinated with these particles were protected from all weight loss and from a lethal encephalitis caused by a high dose of wild-type VSV given intravenously.
We have also tested the immunogenicity of SFVG particles expressing HIV-1 envelope (Env) or VSV nucleocapsid (N) proteins behind a second SFV promoter. These vectors generate strong primary CD8 T cell responses to the foreign proteins as well as memory T cell responses that can be recalled to high levels after boosting.
Results
Induction of Neutralizing Antibodies to VSV G Protein in Mice Inoculated with SFVG Particles Requires Vector Replication. To determine whether the propagating replicon particles were able to induce antibody responses to VSV G protein in animals and whether replication was required for such induction, we inoculated mice by the intramuscular (i.m.) route with 6 ϫ 10 3 infectious units (i.u.) of SFVG particles that were either untreated or inactivated with UV light to prevent RNA replication. After 1 month, serumneutralizing antibody titers to VSV were determined (Fig. 1 Left) . These results showed 100% neutralization of VSV at serum dilutions of 1:160 for SFVG particles but no detectable neutralizing Ab (Ͻ1:20) in animals given the UV-inactivated particles. These results indicate that the incoming G protein on the particles was not present in sufficient amounts to induce VSV-neutralizing antibody and that G protein must be synthesized in infected cells to generate such responses.
We next determined whether the strength of the antibody response to VSV G was dose-dependent. We inoculated mice with 10 5 i.u. of SFVG particles or with 10 5 plaque-forming units (pfu) of VSV. VSV serum-neutralizing titers were determined at 28 days after infection by using pooled serum from each group.
The neutralizing antibody responses to VSV in sera from mice inoculated with the high dose (10 5 i.u.) of SFVG was 1:5,120, 32-fold higher than that induced in mice inoculated with the lower dose (6 ϫ 10 3 i.u.) of SFVG. Remarkably, the neutralizing titer from the animals receiving 10 5 i.u. of SFVG particles was equivalent to that generated by inoculation of the same titer of VSV (Fig. 1 Right) . In an additional experiment, we inoculated mice with 2.5 ϫ 10 5 SFVG particles and found no increase in the VSV-neutralizing antibody titers.
Vaccination with SFVG Particles Protects Mice from Pathogenesis
After VSV Challenge. i.v. injection of wild-type VSV in BALB/c mice causes severe weight loss over 4-5 days and also causes lethal encephalitis in 20-40% of the animals. To determine whether immunization with SFVG particles was sufficient to protect mice from such pathogenesis, 12 mice were immunized i.m. with SFVG particles and then challenged 36 days later with 5 ϫ 10 7 pfu of wild-type VSV by the i.v. route. Following challenge, the mice were weighed daily to follow pathogenesis. The SFVG-immunized mice maintained the same or higher than prechallenge body weights following challenge and showed no signs of pathogenesis. (Fig. 2) . In contrast, all 12 age-matched naive control mice showed dramatic weight loss following the identical challenge, along with other signs of pathogenesis including ruffled fur and hunched posture. In addition, 4/12 of the control mice developed the severe hind-limb paralysis indicative of VSV encephalitis and died or were killed on days 5 and 6. There was a significant difference (p ϭ Ͻ0.05, MannWhitney test) in weight loss between the SFVG-immunized group and the control group, through day 7 after challenge. After day 7, the remaining animals in the control group began to recover to normal weight. The protection from paralysis (encephalitis) was also statistically significant (P ϭ 0.047, Fisher's exact test) between the immunized and control groups.
We also checked VSV-neutralizing antibody titers in individual immunized animals at day 30, 6 days before challenge. They ranged from 1:640 to 1:5120 in the 12 vaccinated animals. The control animals had undetectable VSV-neutralizing antibody titers. The high titer antibodies in the vaccinated animals are consistent with the complete protection observed. injections of SFVG particles, we had not seen any signs of pathogenesis in mice. To determine whether there was any detectable pathogenesis caused by infection by other potentially more pathogenic routes, we gave the SFVG particles by both the i.v. and the intranasal routes (10 5 i.u.). We then weighed the mice daily for 2 weeks and then observed the mice for 60 days and saw no signs of pathogenesis caused by the particles.
Generation of SFVG Replicons Expressing HIVgp140.
To evaluate the ability of infectious SFVG particles to generate cell-mediated immune responses, we generated particles expressing the HIV-1 (IIIB) gp140 gene. This gene encodes a secreted form of HIV Env protein lacking the transmembrane and cytoplasmic portions of gp41 (14) . There is an immunodominant CD8 T cell (p18) epitope (15, 16) in this gp140 protein (BALB/c mice), and we have an MHC I tetramer that recognizes T cells specific for this epitope, allowing precise quantitation of the CD8 T cell response (17) . The gp140 gene was inserted into the pSFVdpG-X vector (18) downstream from a second SFV promoter. To generate the replicons, RNA transcribed in vitro from this vector was used to transfect BHK-21 cells, and infectious particles were recovered after 28 h as described in Materials and Methods. Infectious SFVG-gp140 particles derived from pSFVdpG-gp140 were expected to encode VSV G and HIV gp140 from separate mRNAs.
Coexpression of VSV G and HIVgp140 Proteins in Infected Cells.
To determine whether the SFVG-gp140 particles expressed both VSV G and gp140 proteins, we infected BHK-21 cells with these particles for 20 h. Cells were then fixed, and expression of both gp140 and VSV G was detected by indirect immunofluorescence (Fig. 3) . VSV G protein was expressed predominantly on the cell surface (red, Fig. 3A) , whereas HIVgp140 was expressed in a pattern typical of the endoplasmic reticulum (green, Fig. 3B ) in a focus of infection. The merged image (Fig. 2C) shows that cells expressing VSV G also expressed HIV gp140. The differential interference contrast image of the same field shows that some cells in the periphery of the focus of infection (white arrows) were not yet infected and expressed neither G nor gp140 (Fig. 2D) .
For direct visualization of the sizes of proteins expressed by the SFVG-gp140 particles, we also performed metabolic labeling of infected cells. BHK-21 cells were infected with SFVG, SFVGgp140, or a VSV recombinant expressing gp140 (14) and labeled with [ 35 S]methionine for 1 h. Cell lysates were prepared and either fractionated directly by SDS/PAGE or immunoprecipitated by using antibodies to VSV or HIV Env before PAGE as indicated (Fig. 4) . VSV proteins (L, G, N, P, and M) as well as gp140 are easily seen without immunoprecipitation because of the effective shut-off of host protein synthesis (lane 1). Anti-VSV antibody precipitated all VSV proteins (lane 2), whereas anti-Env antibody precipitated gp140 (lane 3) from the VSVgp140 lysate. Cells infected with SFVG particles expressed VSV G but not gp140 (lanes 4 and 5), whereas cells infected with SFVG-gp140 expressed both G and gp140 (lanes 6 and 7). Mock-infected cells were used as controls (lanes 8 and 9).
SFVG-gp140 Particles Elicit Env-Specific CD8 T Cell Responses.
To determine whether the SFVG vector expressing HIV Env gp140 was able to induce CD8 T cell responses to Env, we vaccinated mice i.m. with SFVG-gp140 particles and used an MHC I tetramer assay employing an H-2 D d tetramer loaded with the immunodominant peptide p18-110 (16) from HIV IIIb Env protein (17) .
Seven days after vaccination with SFVG-gp140, mice had a substantial population of activated Env-specific CD8 T cells (2.3 Ϯ 0.3% CD62L lo , tetramer ϩ , CD8 T cells, Fig. 5 A and B) . The population elicited by SFVG-gp140 was similar to the primary response elicited by the vaccinia vectors (3.5 Ϯ 0.5%, CD62L lo , tetramer ϩ CD8 T cells) in mice that had previously seen only the control SFVG vector (Fig. 5 A and B) . This response is also the same as that generated in naive mice given the vaccinia vector expressing HIV Env (17) . The primary response to Env elicited by SFVG-gp140 was 4-5-fold lower than that elicited by VSVgp140 (Fig. 5B) .
Because of the ability of SFVG-gp140 particles to elicit a strong primary T cell response, we next examined the recall of memory cells after a boost with vaccinia expressing HIV Env. On day 29 after prime, mice were boosted with vaccinia virus (vPE16) expressing the HIV Env protein (19) . Recall Envspecific CD8 T cell responses were measured 6 days after boost at day 35. Mice primed with VSVgp140 or SFVG-gp140 elicited a strong recall response after vPE16 boost. In fact, the Envspecific CD8 T cell response was equivalent after boost when primed with either the VSV or the SFV vector ( Fig. 5B; 21 .2% Ϯ 1.1% and 21.6% Ϯ 3.2%, respectively).
To examine the versatility of our vector system, we also tested an SFVG-N vector that expresses the VSV nucleocapsid protein (18) and analyzed its ability to initiate cellular immune responses. We vaccinated mice i.m. with SFVG-N and looked at the primary and recall responses to VSV N. For these experiments, we used an H-2K b tetramer containing an immunodominant peptide from VSV N (20, 21) .
We found a defined population of N-specific CD8 T cells in the spleens of animals vaccinated with SFVG-N (0.5% CD62L lo , tetramer ϩ ), which were boosted to high levels (12% CD62L lo , tetramer ϩ ) with a vaccinia recombinant [v38 (22) ] expressing VSV N protein.
Discussion
Vaccine vectors based on live viruses or viral replicons are typically potent inducers of long-lasting immune responses in animals. The Semliki Forest virus replicon has been used extensively as an effective single-cycle vaccine vector (1). This vector is normally packaged by using SFV capsid protein and envelope glycoproteins expressed in trans. In the current study, we have taken advantage of our earlier finding that expression of the VSV G protein from the SFV replicon results in budding of infectious membrane-enveloped particles containing VSV G protein and the SFV replicon. We show here that these particles induced potent antibody responses to the VSV G protein in mice and could protect mice from pathogenesis including lethal encephalitis caused by VSV. They also induced strong cellular immune responses to other proteins such as an HIV Env protein expressed from a second transcription unit added to the SFVG replicons.
The hybrid-virus vaccine platform we have described here could have significant advantages over traditional alphavirusbased vectors. Because the VSV G protein is expressed directly from the replicon, there is no requirement for expression of packaging proteins in trans as in other alphavirus systems. In these complementation systems, there is also the potential of reconstituting wild-type alphaviruses through recombination. Because none of the SFV structural protein genes are present in the SFVG vector, reconstitution of wild-type SFV is not possible. Also, the relatively nonspecific packaging of the genomes into infectious vesicles in the absence of a nucleocapsid (6) makes it likely that there will not be a strict packaging limit for the RNA, as there is in alphaviruses or other vectors with well-defined capsid structures. The SFVG particles expressing foreign antigens could be produced in cell lines already approved for vaccine production without any requirement for modification to express complementing proteins in trans.
We initially used the rather cumbersome method of transcribing capped SFVG vector RNA in vitro and then transfecting the RNA onto cells to generate the propagating replicon particles.
More recently, we have tested a DNA-launched version of the SFVG vector by using the pBK-T-SFV1 vector with a CMV promoter (1) to drive expression of the SFVG-gp140 RNA in cells. This system bypasses the in vitro transcription step and greatly simplifies production of infectious particles.
Importantly, we found that the SFVG particles were nonpathogenic in mice even when given by the i.v. route, a route that allows widespread dissemination in the animal. Lack of pathogenesis probably results from inefficient particle production in the absence of a nucleocapsid protein. Pathogenic animal viruses all have capsid or nucleocapsid proteins to allow efficient packaging of their nucleic acids. This low efficiency of packaging of the particles probably prevents spread of infection from initially infected cells and thus rapidly limits the infection. Certainly more extensive studies of potency and potential pathogenesis will have to be undertaken in non-human primate and other animal models before these vectors could be used in clinical trials.
Vaccine vectors based on normal human pathogens are problematic because of the preexisting immunity to the vector in the human population that can limit vector effectiveness. For both VSV and SFV, there is negligible preexisting immunity in humans. However, because viral vaccine vectors express viral proteins in addition to the immunizing antigen, they are potentially limited for reuse or for effective boosting because immunity is generated to the vector proteins in the initial application. For example, with vectors based on live-attenuated VSV, there is a strong antibody response to VSV G protein that prevents boosting with the same vector. However, this block can be overcome by switching to a G protein from a different VSV serotype or a different vesiculovirus in the boosting vector (23) . Presumably, this same strategy of switching G proteins would work for SFVG vectors also. The extensive repertoire of available vesiculovirus glycoproteins could therefore greatly expand the potential of this vaccine strategy. The G protein-based propagating replicon strategy could also likely be extended to other alphavirus replicon systems (4) to further extend vaccine applications.
Materials and Methods
Plasmid Construction. To construct pSFVG-gp140, a 2022-bp DNA fragment encoding the HIVgp140 protein (IIIB strain) was amplified by PCR with VENT polymerase (NEB) from pBSEnvG709 (24) by using the forward primer 5Ј-GATCGATCG GGCCCAACAT GAGAGTGAAG GAGAAATATC AGC-3Ј and the reverse primer 5ЈATCTGGCT ACGGGCCCTC AACTTGCCC ATTTATCTAATTCC-3Ј. Both of the primers contained an ApaI site. The PCR product was digested with ApaI, purified, and ligated into the pSFV1-Gdp vector linearized with ApaI (18) . The correct sequence of the gp140-insert was verified (Yale Keck Facility).
Transcription of RNA and Transfection to Generate Infectious Particles. To generate the infectious RNA genome of the propagating replicons, pSFV1-G and pSFVG-gp140 plasmids were linearized with SpeI and transcribed for 2 h at 37°C in a 40-l reaction mixture. The reaction was a modification of the Ampliscribe SP6 transcription kit (Epicentre technologies) containing SP6 reaction buffer, 5 mM each of ATP, CTP, and UTP, 1 mM GTP, 4 mM m 7 G(ppp)G RNA cap analog (NEB S1404L), 10 mM DTT, and 2 l of SP6 polymerase. The transcription reactions were stored at Ϫ80°C.
Transfection of cells for growing stocks of propagating replicons was performed as follows: 4 ϫ 10 6 BHK-21 cells were plated the day before transfection on 10-cm diameter plates. They were then transfected with 60 l of transcription reaction in 9 ml of serum-free DMEM containing 90 l of a cationic liposome reagent containing dimethy-dioctadecyl ammonium bromide (25) as described (6) . The cells were scraped into the medium at 28 h after transfection and sonicated by using a Branson 450 sonicator to release infectious particles. After sonication, cell debris was removed by centrifugation for 8 min at 625 ϫ g in a table-top centrifuge, and the supernatants were transferred to new tubes. For concentration of the stocks, supernatants were transferred to Beckman ultraclear tubes and centrifuged at 40,000 rpm for 1 h in a Beckman an SW50.1 rotor. The infectious particles were resuspended in a volume of PBS that concentrated the particles 40-fold.
Immunofluorescence Microscopy. For titration of the stocks, BHK-21 cells plated on coverslips were infected for 21 h with different dilutions of the virus, fixed with 3% paraformaldehyde, and incubated with a 1:200 dilution of monoclonal antibodies (26) to VSV G protein followed by Alexa Fluor 488 goat anti-mouse IgG (HϩL) (Invitrogen) diluted 1:250. Green fluorescent areas of infected cells or plaques were counted on an Olympus CK40 microscope equipped with a ϫ10 objective, and titers were calculated. Infectious particle titers in the range of 1-5 ϫ 10 7 per ml were obtained, depending on the construct.
For visualization of both VSVG and HIVgp140 proteins after transfection with pSFVG-gp140 or infection with SFVG-gp140 particles, BHK-21 cells were fixed and incubated with anti VSV-G antibody as above followed by Alexa Fluor 594 goat anti-mouse IgG (1:500) secondary antibody. The cells were then permeabilized with 1% Triton X-100 and incubated with a 1:100 dilution of polyclonal sheep anti-HIVgp120 antiserum (NIH AIDS Research and Reference Reagent Program) followed by incubation with FITC-conjugated donkey anti-sheep serum diluted 1:50. Cells were observed with a Nikon Eclipse 80i fluorescence microscope equipped with a Nikon Plan Apochromat ϫ60 oil objective and a Photometrics CoolSnap camera.
[ 35 S]Methinonine Labeling, Immunoprecipitation, and SDS/PAGE. BHK-21 cells grown to Ϸ50% confluency on 35-mm-diameter plates were infected with SFVG or SFVG-gp140 particles at a multiplicity of infection of one. Infected cells were incubated at 37°C for 5 h. The medium was removed, and cells were washed twice with methionine-free Dulbecco's modified Eagle's medium (DMEM). Then 1 ml of methionine-free DMEM containing 100 Ci (1 Ci ϭ 37 GBq) of [ 35 S]methionine was added to each plate for 1 h at 37°C. To prepare labeled cell extracts, the medium was removed, and the cells were washed twice with PBS and lysed in 500 l of detergent solution (1% Nonidet P-40,
